Pharmaceuticals & Medical Research

TradingKey - Regeneron stock forecast: REGN jumped 13.33% after a big Q3 beat driven by full Dupixent profits, with $930.46 the next test and RSI overbought.

TradingKey - On October 30, AstraZeneca (AZN) shares rose more than 5% in pre-market trading. The company's third-quarter revenue and earnings both exceeded market expectations, while it reaffirmed its full-year guidance and announced a restructuring plan expected to unlock $1.5 billion in annual benefits, bolstering investor confidence in its medium- to long-term growth prospects.

TradingKey - On October 29, Eli Lilly (LLY) reported third-quarter results that beat market expectations and raised its full-year revenue guidance once again. Driven by sustained growth in demand for Mounjaro and Zepbound, the company's quarterly revenue reached $24.397 billion, up 39% year-over-year and significantly above Wall Street's forecast of approximately $22.6 billion. Following the announcement, Eli Lilly's stock rose more than 5% in pre-market trading.

TradingKey - Moderna stock forecast: MRNA falls 19% in two days despite positive melanoma vaccine data, with $181.36 support now deciding whether the uptrend holds.

TradingKey - On October 22, Eastern Time, Moderna (MRNA) and Merck released Phase III melanoma trial data for Intismeran autogene, a personalized cancer vaccine. Following the announcement, Moderna's stock price plunged, closing down 20.14% at $196.31 for the day after touching an intraday low of $195.23. Although the data showed that the primary efficacy endpoints met expectations, why did the stock price crash?

On October 22 Eastern Time, Moderna (MRNA) shares tumbled as much as 25% intraday. As of press time, the stock remained down 24.24% at $186.23. Reportedly, full Phase 3 data for the melanoma vaccine jointly developed by the company and Merck (MRK) is set to be released soon, while rumors circulated in the market that the trial results were leaked in advance, though this has not been officially confirmed.